Download Week 7 (2015 02 14)

Biobank literature update week 07 (2015)
1. Willemse EA, Koel-Simmelink MJ, Durieux-Lu S, van der Flier WM, Teunissen CE: Standard biobanking conditions prevent evaporation of body fluid samples.
Clin.Chim.Acta 2015.
Abstract: Pre-analytical variation in biobanking procedures, e.g., long-term storage, could confound biomarker outcomes. We investigated evaporation in various
body fluids at different storage temperatures and storage durations. Biobank sample tubes (Sarstedt 72.694.007) filled with water in different volumes (50, 100,
250, 500, 750, 1000, 1250, 1500mul) were stored at different temperatures (-80 degrees C, -20 degrees C, 4 degrees C, room temperature (RT)) for 4.5years and
weighed at regular intervals. Next, saliva, serum, plasma, and CSF were stored in different volumes (50, 250, 500, 1000mul) at different temperatures (-80 degrees
C, -20 degrees C, 4 degrees C, RT) for 2years. An extra set of CSF was stored in tubes with safe-lock cap (Eppendorf 0030 120.086) instead of a screw cap with
o-ring. No evaporation of water stored in biobanking tubes at -80 degrees C or -20 degrees C occurred over 4.5years. Storage of saliva, serum, plasma, and CSF at
-80 degrees C or -20 degrees C, monitored over 2years, protected these samples from evaporation too. At 4 degrees C, evaporation was minor, approximately 1.5%
(50mul) or 0% (1mL) yearly, where at RT it ranged from 38% (50mul) to 2% (1mL). No differences were observed between different body fluids, nor between tube
caps. Our data provide support for long-term biobanking conform current biobanking guidelines, encouraging retrospective use of clinical cohorts
2. Dhiman GJ, Amber KT, Goodman KW: Comparative outcome studies of clinical decision support software: limitations to the practice of evidence-based system
acquisition. J.Am.Med.Inform.Assoc. 2015.
Abstract: Clinical decision support systems (CDSSs) assist clinicians with patient diagnosis and treatment. However, inadequate attention has been paid to the
process of selecting and buying systems. The diversity of CDSSs, coupled with research obstacles, marketplace limitations, and legal impediments, has thwarted
comparative outcome studies and reduced the availability of reliable information and advice for purchasers. We review these limitations and recommend several
comparative studies, which were conducted in phases; studies conducted in phases and focused on limited outcomes of safety, efficacy, and implementation in
varied clinical settings. Additionally, we recommend the increased availability of guidance tools to assist purchasers with evidence-based purchases. Transparency
is necessary in purchasers' reporting of system defects and vendors' disclosure of marketing conflicts of interest to support methodologically sound studies. Taken
together, these measures can foster the evolution of evidence-based tools that, in turn, will enable and empower system purchasers to make wise choices and
improve the care of patients
3. D'Abramo F: Biobank research, informed consent and society. Towards a new alliance? J.Epidemiol.Community Health 2015.
Abstract: With the rise of -omics disciplines and biobank research, personal data and biosamples crossing national borders pose new ethical questions. In this
article, informed consent, as originally conceived, is shown as not being sufficient to address aims of research and interests of patients any more. Therefore the
author has, after having scrutinised issues in biobanking, sketched a model of dynamic consent and a manner of scrutinising ethical issues through empirical data